New York, May 12, 2026, 14:02 EDT
- PACS surged roughly 23% Tuesday afternoon, with Q1 earnings, revenue, and outlook all topping what skeptics had been expecting.
- Stronger facility occupancy, an improved skilled nursing mix, and a higher adjusted EBITDA outlook for 2026 all factored into the move. PACS Group, Inc. also unveiled a fresh $250 million buyback authorization.
- The bear argument sticks around: PACS continues to wrestle with internal-control issues, plus DOJ and SEC probes remain active, both highlighted in its most recent 10-Q.
PACS Group shares surged Tuesday, jumping to $39.30 in early afternoon trading in New York—a gain of $7.40, or 23.2%. After opening at $39.00, the stock hit $41.63 at its peak, and momentum held, with volume topping 2.1 million shares and prices well above the previous close.
It’s a straightforward story for PACS. The company surprised the market with a much simpler earnings narrative: Q1 revenue up 11.2% to $1.42 billion, net income at $80.7 million (that’s a sharp move from $28.4 million), and adjusted EBITDA surged 74.6%, landing at $170.4 million.
The shift came with a reset in expectations. According to MT Newswires, PACS delivered Q1 EPS of $0.50, topping the FactSet consensus by a dime, and revenue hit $1.42 billion, ahead of the $1.36 billion forecast. For a stock still working through the aftermath of a turbulent filing and regulatory patch, a result like that carries extra weight.
The real jolt came from the guidance. PACS bumped its adjusted EBITDA target for 2026 up to a range of $605 million to $625 million, up from the earlier $555 million to $575 million. Revenue guidance stays put at $5.65 billion to $5.75 billion, though that forecast now strips out future acquisitions—those had been baked in before. CFO Carey Hendrickson credited the increase to “excellent performance across both ramping and mature cohorts.” PACS Group, Inc.
Investors drove the chart higher after spotting operating leverage—not just headline sales gains. PACS managed to widen the gap between revenue and costs: total revenue jumped 11.2%, while operating expenses climbed only 5.8%. Same-store skilled nursing revenue advanced 8.0%. Occupancy ticked up to 90.9% from 89.6%. Skilled mix, which tracks higher-acuity patients who typically command better pay, edged up 50 basis points, or half a point.
PACS pulled in a $23.3 million revenue boost from California’s Workforce & Quality Incentive Program last quarter—$16.3 million of that flowed through adjusted EBITDA. The market caught on quickly. While the program’s payout is a genuine cash win, it doesn’t translate to a recurring margin lift.
The tone from management struck a balance—confident, but not overreaching. Hendrickson pointed out PACS wrapped up the quarter holding around $800 million in available liquidity, with about $250 million of that in cash. Net leverage? Just 0.1 times. She added that the buyback gives PACS a way to step in if management feels the shares are “undervalued.” The Motley Fool
The $250 million buyback plan gave investors a boost, signaling management’s willingness to return capital instead of focusing solely on facility acquisitions. But the repurchase authorization isn’t binding—PACS isn’t required to buy any shares, there’s no set end date, and the board can alter, suspend, or cancel it at will.
This wasn’t just a one-name move. Ensign Group tacked on roughly 4.0%, Pennant Group advanced 2.8%, and National HealthCare edged 0.4% higher in recent action—helping lift the broader long-term care and post-acute names. PACS stood out, though, with the strongest company-specific spark.
Bulls point to PACS scaling its model effectively. The company reports its subsidiaries now run 324 post-acute care facilities spanning 17 states. This quarter brought higher occupancy, an improved skilled mix, and robust cash flow—net cash from operating activities jumped to $236.3 million, up from $150.2 million the previous year.
The bearish argument kicks off with questions about earnings quality and wraps up with legal risks. Timing those quality incentive payments isn’t straightforward—Hendrickson told listeners the payments are “not included in our guidance” since they might fall into a different quarter. That sheds light on the conservative guidance, but it complicates things for investors trying to split out core facility gains from any upside linked to the programs. The Motley Fool
But the bigger headache? Controls and probes. PACS admitted that, as of March 31, its disclosure controls were still ineffective—material weaknesses remain unresolved. The 10-Q details a DOJ look into Medicare issues, referral ties, PDPM reimbursements, and COVID-era waiver policies. There’s also an SEC investigation covering accounting, reporting, and internal controls.
Tuesday’s jump isn’t exactly a green light—it’s a fresh valuation. Investors were willing to pay more after PACS managed to post growth, solid cash generation, and raised profit guidance, even as regulatory issues linger. The stock’s up, but it’s hardly straightforward.
